By Elizabeth O'Brien

Only a narrow slice of consumers will benefit initially from TrumpRx, the Trump administration's high-profile initiative to lower drug costs for Americans, experts say.

TrumpRx.gov made its debut on Thursday, offering discounted cash prices on about 40 drugs from the following manufacturers: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer. People who buy the drugs directly, via a TrumpRx coupon at the pharmacy, or from the manufacturer, bypassing any health insurance, are eligible for the discounts.

The administration focused the launch on drugs that receive some of the highest spending and that aren't usually covered by insurance, such as GLP-1 weight-loss drugs. The site lists a 30-day supply of Novo Nordisk's Wegovy 1.5 mg weight loss-pill for $149, down from an original price of $1,349.

Deals on additional drugs from other manufacturers will become available in the coming months, the administration said.

About 25 million Americans have no health insurance, according to Courtney Yarbrough, assistant professor at Emory University's Rollins School of Public Health, who says this group stands to gain the most from TrumpRx. "It's certainly not reordering the way most Americans buy drugs," Yarbrough said.

The discounts came via negotiations between the Trump administration and drug manufacturers that aren't codified into law, said Merith Basey, CEO of Patients for Affordable Drugs, an advocacy group. Basey says key questions for patients are how long will the discounts be available, will prices be subject to change, and will pharmacies honor them?

The terms and conditions on the TrumpRx site say the Wegovy pill offer is valid only at participating pharmacies and is subject to change or discontinuation without notice. The offer isn't available to patients enrolled in Medicare, Medicaid, or other federal or state insurance programs.

The Trump administration has called TrumpRx the result of its "most favored nation" pricing, referring to the policy goal of pegging the prices Americans pay to the lowest costs in the developed world. Experts surveyed recently by the journal "Health Affairs" had mixed opinions on whether most favored nation pricing would affect prices.

Some 35% of those surveyed agreed that most favored nation pricing would substantially reduce average net prices of branded drugs, while 20% disagreed. Among those who disagreed, some noted that savings may be limited as manufacturers aim to reduce price concessions.

"As part of their deals with the Trump administration, pharmaceutical companies have also agreed to offer all future drugs at discounted Most Favored Nations pricing -- this is an unambiguous gamechanger for American patients in the years to come thanks to President Trump's leadership," White House spokesman Kush Desai told Barron's.

Consumers with health insurance who opt to use TrumpRx should keep in mind that cash purchases of medications typically don't count toward their deductible for the year.

Write to Elizabeth O'Brien at elizabeth.obrien@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

February 06, 2026 17:13 ET (22:13 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.